Chinook Therapeutics, Inc. – NASDAQ:KDNY

Financial Health
0
1
2
3
4
5
6
7
8
9

Chinook Therapeutics stock price monthly change

+6.46%
month

Chinook Therapeutics stock price quarterly change

+74.62%
quarter

Chinook Therapeutics stock price yearly change

+96.93%
year

Chinook Therapeutics key metrics

Market Cap
2.70B
Enterprise value
1.33B
P/E
-7
EV/Sales
217.79
EV/EBITDA
-7.48
Price/Sales
230.19
Price/Book
3.19
PEG ratio
0.23
EPS
-3.48
Revenue
5.84M
EBITDA
-221.24M
Income
-243.21M
Revenue Q/Q
141.14%
Revenue Y/Y
-89.23%
Profit margin
-3065.68%
Oper. margin
-2824.67%
Gross margin
0%
EBIT margin
-2824.67%
EBITDA margin
-3782.6%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Chinook Therapeutics stock price history

Chinook Therapeutics stock forecast

Chinook Therapeutics financial statements

Chinook Therapeutics, Inc. (NASDAQ:KDNY): Profit margin
Sep 2022 2.50M -54.28M -2170.69%
Dec 2022 512K -61.8M -12070.31%
Mar 2023 1.82M -60.17M -3291.96%
Jun 2023 1.00M -66.94M -6641.27%
Chinook Therapeutics, Inc. (NASDAQ:KDNY): Debt to assets
Sep 2022 590336000 115.7M 19.6%
Dec 2022 574084000 132.14M 23.02%
Mar 2023 543875000 131.48M 24.18%
Jun 2023 488811000 131.77M 26.96%
Chinook Therapeutics, Inc. (NASDAQ:KDNY): Cash Flow
Sep 2022 -25.31M -13.13M 18.83M
Dec 2022 -36.82M 2.47M 23.69M
Mar 2023 -50.66M 32.43M 21.26M
Jun 2023 -61.19M 68.00M 2.01M

Chinook Therapeutics alternative data

Chinook Therapeutics, Inc. (NASDAQ:KDNY): Employee count
Aug 2023 214
Sep 2023 214
Oct 2023 214
Nov 2023 214
Dec 2023 214
Jan 2024 214
Feb 2024 214
Mar 2024 214
Apr 2024 214
May 2024 214
Jun 2024 214
Jul 2024 214

Chinook Therapeutics other data

33.33% -52.47%
of KDNY is owned by hedge funds
21.45M -36.69M
shares is hold by hedge funds

Chinook Therapeutics, Inc. (NASDAQ:KDNY): Insider trades (number of shares)
Period Buy Sel
Sep 2022 10000 0
Oct 2022 0 10917
Nov 2022 0 10000
Dec 2022 0 45770
Jan 2023 0 53389
Feb 2023 0 15046
Mar 2023 0 400000
Apr 2023 0 321732
May 2023 0 1155
Aug 2023 0 1168
Transaction Date Insider Security Shares Price per share Total value Source
Sale
KING ANDREW JAMES officer: Chief Scientific Officer
Common Stock 1,168 $39.03 $45,586
Option
KING ANDREW JAMES officer: Chief Scientific Officer
Common Stock 3,333 N/A N/A
Option
KING ANDREW JAMES officer: Chief Scientific Officer
Restricted Stock Units 3,333 N/A N/A
Sale
GREENMAN WILLIAM MARINER director Common Stock 1,155 $23.3 $26,912
Option
GREENMAN WILLIAM MARINER director Common Stock 3,300 N/A N/A
Option
GREENMAN WILLIAM MARINER director Restricted Stock Units 3,300 N/A N/A
Option
AKKARAJU SRINIVAS director
Common Stock 3,300 N/A N/A
Option
AKKARAJU SRINIVAS director
Restricted Stock Units 3,300 N/A N/A
Option
HAGHIGHAT ROSS director
Common Stock 3,300 N/A N/A
Option
HAGHIGHAT ROSS director
Restricted Stock Units 3,300 N/A N/A
Friday, 18 August 2023
accesswire.com
Friday, 11 August 2023
globenewswire.com
Saturday, 5 August 2023
accesswire.com
Friday, 4 August 2023
accesswire.com
Thursday, 3 August 2023
accesswire.com
Wednesday, 2 August 2023
GuruFocus
Tuesday, 20 June 2023
The Motley Fool
Tuesday, 13 June 2023
MarketBeat
Monday, 12 June 2023
InvestorPlace
GlobeNewsWire
Market Watch
The Motley Fool
Investopedia
Proactive Investors
InvestorPlace
Barrons
Market Watch
Market Watch
Tuesday, 9 May 2023
Zacks Investment Research
Friday, 5 May 2023
GlobeNewsWire
Thursday, 27 April 2023
GlobeNewsWire
Thursday, 20 April 2023
Seeking Alpha
Tuesday, 11 April 2023
GlobeNewsWire
Tuesday, 28 March 2023
GlobeNewsWire
Tuesday, 7 March 2023
GlobeNewsWire
Monday, 27 February 2023
Zacks Investment Research
Wednesday, 22 February 2023
Seeking Alpha
Monday, 13 February 2023
Seeking Alpha
Tuesday, 7 February 2023
GlobeNewsWire
Friday, 6 January 2023
Seeking Alpha
  • When is Chinook Therapeutics's next earnings date?

    Unfortunately, Chinook Therapeutics's (KDNY) next earnings date is currently unknown.

  • Does Chinook Therapeutics pay dividends?

    No, Chinook Therapeutics does not pay dividends.

  • How much money does Chinook Therapeutics make?

    Chinook Therapeutics has a market capitalization of 2.70B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 88.13% to 6.13M US dollars.

  • What is Chinook Therapeutics's stock symbol?

    Chinook Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KDNY".

  • What is Chinook Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Chinook Therapeutics?

    Shares of Chinook Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Chinook Therapeutics's key executives?

    Chinook Therapeutics's management team includes the following people:

    • Mr. Eric L. Dobmeier Pres, Chief Executive Officer & Director(age: 56, pay: $695,910)
    • Dr. Alan Glicklich M.D. Chief Medical Officer(age: 63, pay: $437,050)
    • Mr. Tom Frohlich Chief Operating Officer(age: 49, pay: $426,430)
  • How many employees does Chinook Therapeutics have?

    As Jul 2024, Chinook Therapeutics employs 214 workers.

  • When Chinook Therapeutics went public?

    Chinook Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 6 Oct 2020.

  • What is Chinook Therapeutics's official website?

    The official website for Chinook Therapeutics is chinooktx.com.

  • Where are Chinook Therapeutics's headquarters?

    Chinook Therapeutics is headquartered at 400 Fairview Avenue North, Seattle, WA.

  • How can i contact Chinook Therapeutics?

    Chinook Therapeutics's mailing address is 400 Fairview Avenue North, Seattle, WA and company can be reached via phone at +20 64 857241.

Chinook Therapeutics company profile:

Chinook Therapeutics, Inc.

chinooktx.com
Exchange:

NASDAQ

Full time employees:

214

Industry:

Biotechnology

Sector:

Healthcare

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

400 Fairview Avenue North
Seattle, WA 98109

CIK: 0001435049
ISIN: US00739L1017
CUSIP: 16961L106